Cart
×
“Dear Mom” Giving Thanks for Mom This Mother’s Day
Mother’s Day is a reminder to love our moms a little extra and be thankful for all that they do for us. For boys with Duchenne, it’s a reminder of […]
Duchenne Community Letter from PTC Therapeutics
May 8, 2017 Dear Duchenne Families, Today we shared our plans for the launch of EMFLAZA™ (deflazacort), the first FDA-approved corticosteroid for Duchenne muscular dystrophy patients age 5 and […]
Eighth Annual Champions to CureDuchenne Gala Raises More Than $378,000 Towards Finding a Cure for Duchenne Muscular Dystrophy
Austin, Texas, May 4, 2017 – On April 8, hundreds gathered at The University of Texas Golf Club for a common goal, raising awareness and funds to help CureDuchenne in […]
Anaheim Ducks Captain Ryan Getzlaf Supports CureDuchenne In 7th Annual Getzlaf Golf Shootout to Help Save Lives of Those with Duchenne
Newport Beach, Calif., May 1, 2017 – Hitting a hole in one will feel twice as nice at the 7th Annual Getzlaf Golf Shootout, hosted by Anaheim Ducks Captain Ryan […]
HOPE Clinical Trial Provides Hope for Duchenne Families
CureDuchenne is pleased to see the positive preliminary data from Capricor Therapeutics on their HOPE clinical trial in Duchenne muscular dystrophy. CureDuchenne Ventures helped fund this clinical trial to address […]
Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy
LOS ANGELES, April 25, 2017 /PRNewswire/ — Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company developing first-in-class biological therapies for cardiac and other medical conditions, today announced positive top-line results […]
PTC Therapeutics Completes Acquisition of Emflaza™ for the Treatment of Duchenne Muscular Dystrophy in the U.S.
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has completed its acquisition of all rights to Emflaza™ (deflazacort) for the treatment of Duchenne muscular dystrophy (DMD) in the U.S. Execution […]
Duchenne Community Message From PTC Therapeutics on Close of Emflaza Acquisition
April 20, 2017 Dear Duchenne Community, Today we announced that we have completed our acquisition of Emflaza™ (deflazacort), the first FDA-approved, anti-inflammatory therapy for Duchenne Muscular Dystrophy (DMD) patients […]
CRISPR Corrects Duchenne-Causing Mutations
Using CRISPR-Cpf1 gene editing, researchers have fixed mutations that cause a form of muscular dystrophy in cultured human cardiomyocytes and a mouse model. By Anna Azvolinsky | April 12, 2017 […]